ArticleFrontiers in human neuroscience2026
Multimodal biomarkers of response to transcutaneous auricular vagus nerve stimulation in disorders of consciousness: a study protocol.
Article in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with disorders of consciousness (DOC) have limited options for arousal-promoting interventions. Transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive neuromodulation technique, has shown potential to improve conscious behaviors in a subset of patients with DOC. However, substantial interindividual variability in treatment response remains, and reliable objective biomarkers for identifying patients who may benefit are still lacking. This study is designed as a single-center, prospective, exploratory clinical study. A total of 50 patients with DOC will be consecutively recruited from the Neurosurgical Ward for DOC at Beijing Tiantan Hospital, Capital Medical University. All enrolled patients will receive 4 weeks of taVNS treatment in addition to standard rehabilitation. Assessments using the Coma Recovery Scale-Revised (CRS-R), electroencephalography (EEG), and functional near-infrared spectroscopy (fNIRS) will be performed at baseline, week 2, and week 4 of treatment. The primary outcome will be the observed change in the CRS-R total score from baseline to week 4. Secondary outcomes will include changes in CRS-R subscale scores, diagnostic transitions in consciousness state, and prespecified EEG and fNIRS features associated with treatment response. Responders will be defined as patients with an increase of at least 3 points in the CRS-R total score from baseline to week 4. Because this is an uncontrolled single-arm study, the findings will be interpreted as exploratory and hypothesis-generating rather than as evidence of causal efficacy. This study aims to characterize behavioral, electrophysiological, and hemodynamic changes during taVNS plus standard rehabilitation and to identify candidate multimodal biomarkers associated with observed improvement, thereby providing a methodological basis for future randomized controlled trials in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.